Steve Jenkinson PhD

VP, Drug Discovery and Safety Assessment, USA

Steve J v2
Steve Jenkinson PhD
VP Drug Discovery and Safety Assessment, USA

Steve Jenkinson is a thought leader in his field with a strong background in drug discovery and secondary pharmacology. He has managed drug discovery programmes across multiple therapeutic areas and stages, ranging from target identification to the nomination of candidates for preclinical development.

He has over 25 years leadership of drug discovery projects with GSK and Tanabe Research Laboratories and  joins Metrion from Pfizer where, as Senior Director, he established, developed and led the secondary pharmacology and high throughput screening team. Additionally, Steve is co-chair of the IQ DruSafe Secondary Pharmacology working group and a member of the FDA’s HESI Pro-Arrhythmia group.

Steve completed two Postdoctoral research fellowships, the first at the Scripps Institute in La Jolla and the second at the Neurosciences Institute in San Diego, before returning to the UK to begin his drug discovery career at Pfizer, Sandwich. Steve received his undergraduate degree in Pharmacology from the University of Glasgow and PhD in Molecular Pharmacology from the University of Leicester. He also completed a Master’s Degree in Clinical Research at the University of California, San Diego.

Wave Background thinner 01 1
Metrion Ion Channel Screening Icon 01

Let’s work together

What are your specific ion channel and assay needs?

If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.